trans-1-methyl-4-(methyloxy)cyclohexaneamine hydrochloride | 950773-03-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trans-1-methyl-4-(methyloxy)cyclohexaneamine hydrochloride
• 英文别名: trans-1-methyl-4-(methyloxy)cyclohexanamine monohydrochloride
• CAS: 950773-03-2
• 化学式: C₈H₁₇NO*ClH
• 分子量: 179.69
• InChiKey: IKUZONMLLUJBJY-KMMPGQJCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.71
• 重原子数：
  11.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.25
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  trans-1-methyl-4-(methyloxy)cyclohexaneamine hydrochloride 在 palladium 10% on activated carbon 氨 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 20.0~80.0 ℃ 、344.75 kPa 条件下， 反应 24.0h， 生成 1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinamine
  参考文献：
  名称：

  WO2007/107565

  摘要：

  公开号：
• 作为产物：
  描述：

  cis/trans-1-methyl-4-(methyloxy)cyclohexanecarboxylic acid 在 盐酸 、 氯化亚砜 、 叠氮磷酸二苯酯 、 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 水 、 甲苯 为溶剂， 反应 10.5h， 生成 trans-1-methyl-4-(methyloxy)cyclohexaneamine hydrochloride
  参考文献：
  名称：

  WO2007/107565

  摘要：

  公开号：

文献信息

• [EN] COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE<br/>[FR] COMPOSÉS PRÉSENTANT UNE ACTIVITÉ AU NIVEAU DU RÉCEPTEUR M1 ET LEURS UTILISATIONS EN MÉDECINE
  申请人：GLAXO GROUP LTD

  公开号：WO2009037294A1

  公开（公告）日：2009-03-26

  Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

  提供具有公式(I)或其盐的化合物：其中R4、R5、R6、Q、A、Y和R按描述定义。披露了这些化合物作为药物的使用和在制造用于治疗精神病性障碍、认知障碍和阿尔茨海默病药物中的应用。本发明还公开了包含这些化合物的药物组合物。
• Compounds which have activity at M1 receptor and their uses in medicine
  申请人：Cooper David Gwyn

  公开号：US20100204272A1

  公开（公告）日：2010-08-12

  Compounds of formula (I) or a salt thereof are provided: wherein R 4 , R 5 , R 6 , Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

  本发明提供了化学式(I)的化合物或其盐：其中R4，R5，R6，Q，A，Y和R的定义如说明书中所定义。本发明还揭示了将该化合物用作药物以及制造用于治疗精神障碍，认知障碍和阿尔茨海默病的药物的用途。本发明还揭示了包含该化合物的制药组合物。
• BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE
  申请人：COOPER David Gwyn

  公开号：US20120041027A1

  公开（公告）日：2012-02-16

  Compounds of formula (I) and salts and solvates are provided: wherein Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

  提供公式(I)的化合物、盐和溶剂化合物，其中公式(I)如下： 该化合物可用于治疗精神失常和认知障碍等疾病。
• Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine
  申请人：Cooper David Gwyn

  公开号：US20120316196A1

  公开（公告）日：2012-12-13

  Compounds of formula (I) or a salt thereof are provided: wherein R 4 , R 5 , R 6 , Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

  提供化学式(I)的化合物或其盐： 其中R4、R5、R6、Q、A、Y和R的定义如说明书所述。本发明还公开了将该化合物用作药物治疗精神疾病、认知障碍和阿尔茨海默病以及制造药物的用途。本发明还公开了包含该化合物的制药组合物。
• The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists
  作者：Dale J. Johnson、Ian T. Forbes、Steve P. Watson、Vincenzo Garzya、Graeme I. Stevenson、Graham R. Walker、Harminder S. Mudhar、Sean T. Flynn、Paul A. Wyman、Paul W. Smith、Graham S. Murkitt、Adam J. Lucas、Claudette R. Mookherjee、Jeannette M. Watson、Jane E. Gartlon、Andrea M. Bradford、Fiona Brown

  DOI：10.1016/j.bmcl.2010.07.097

  日期：2010.9

  A series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles are reported which were found to be potent and selective muscarinic M-1 agonists. By control of the physicochemical characteristics of the series, particularly the lipophilicity, compounds with good metabolic stability and excellent brain penetration were identified. An exemplar of the series was shown to be pro-cognitive in the novel object recognition rat model of temporal induced memory deficit. (c) 2010 Elsevier Ltd. All rights reserved.